Comments
Commented by André Will-Laudien on December 13th, 2023 | 07:45 CET
Uranium, lithium or gold? The climate conference tells us which way to go! BYD, Globex Mining, VW and Mercedes!
At the international climate conference in Dubai, several Arab countries sharply criticized and ultimately rejected the global move away from fossil fuels. The move by Western countries is an "aggressive attack", said Kuwaiti Oil Minister Saad Hamad Nasser al-Barrak yesterday, Tuesday. "I am astonished by this extraordinary insistence on depriving people and many countries of their basic source of energy. This approach is racist and colonialist," al-Barrak continued. This means that there will be no decision on a global phase-out of oil and gas with the OPEC states. Therefore, the current World Climate Conference is likely to be inconclusive or conclude with unilateral declarations from the EU. However, there is much to suggest that commodities that positively impact the global climate will remain on the import list of industrialized countries. Which shares should be considered in this mixed situation?
Read
Commented by Fabian Lorenz on December 13th, 2023 | 07:30 CET
Several 100% upside potential? BioNTech, Bayer, Cardiol Therapeutics and Evotec in analyst check
We take a look at analysts' opinions on biotech and pharmaceutical stocks. Jefferies recently renewed its "Buy" recommendation for Evotec with a target price of EUR 34. The latest partnerships confirm that the Company's unique business model is working. The situation at Bayer is quite different. While the CEO is announcing radical changes, analysts are slashing their price targets, in some cases significantly. In contrast, analysts believe that Cardiol Therapeutics could achieve several 100% gains. The cash register is full to bursting, and an exciting news flow can be expected in 2024. At BioNTech, only the cash position is currently convincing. However, this is not enough for a buy recommendation.
Read
Commented by Armin Schulz on December 13th, 2023 | 06:40 CET
Rock Tech Lithium, Klimat X Developments, Plug Power - Which GreenTechs have potential?
GreenTech companies have become increasingly important in recent years as they focus on developing and disseminating technologies that promote environmental protection. One example of this is lithium refinement, which is required for the production of batteries for electric vehicles. Another crucial topic is CO2 certificates, which companies can purchase to offset their emissions. Hydrogen technology is also becoming increasingly important, as it is seen as a clean alternative to fossil fuels. We have selected a candidate from each sector and are examining their potential.
Read
Commented by André Will-Laudien on December 12th, 2023 | 13:40 CET
Game Changer in Cancer - The Biotech Gold List for 2024! MorphoSys, Defence Therapeutics, BioNTech and Bayer
The International Agency for Research on Cancer estimates the number of cancer deaths worldwide for the year 2022 to be around 10 million. However, the number of new cancer cases in the same year amounted to around 20 million, and cancer is still considered incurable. Lung cancer remains the sad frontrunner, claiming the most lives worldwide. Colorectal and stomach cancer follow at a considerable distance. However, since the original launch of the "Cancer Moonshot" in 2016, the fight against this incurable disease in the US has made some progress in the realization of therapies. Recently, there has been an increase in success stories from many biotech companies, and investors' enthusiasm is palpable once again. Where are the Biotech game changers lurking for the 2024 investment year?
Read
Commented by Armin Schulz on December 12th, 2023 | 06:50 CET
BioNTech, Defence Therapeutics, Bayer - Golden times for the biotech and pharma industry?
With the arrival of winter, people are increasingly worried about illnesses such as coronavirus and influenza. The current wave of diseases and the new coronavirus variant are increasing the demand for medicines, which could positively impact the shares of pharmaceutical and biotech companies. Biotech's success in drug development for COVID-19 vaccines has allowed the industry to flourish over the past two years. But after the boom came the crash. However, the stock market always moves in cycles. The current challenges in the healthcare sector, such as the rising number of cancer cases, could, therefore, mean golden times for pharmaceutical and biotech companies, as they not only contribute to improving global health but also offer attractive returns for investors.
Read
Commented by André Will-Laudien on December 12th, 2023 | 06:40 CET
Climate conference and Venice turns green! Oil remains in demand; goodbye hydrogen? Nel ASA, Prospera Energy and Plug Power in Focus
Too little, too slow, too half-hearted! Climate activists in Italy have drawn attention to themselves with a spectacular campaign. The "Extinction Rebellion" group members painted the famous Grand Canal in Venice fluorescent green. Some activists abseiled from the Rialto Bridge over the central canal of the northern Italian lagoon city on Saturday afternoon and poured dye into the water. Their action was intended to protest against the "ridiculous progress" made at the COP28 World Climate Conference in Dubai. "We are tired, we have had enough of being taken for fools by our governments and knowing that our future is in danger while politicians do nothing," they said in a statement to the press. How do we tackle the energy issues of the future? A look at selected energy stocks paints a clear picture.
Read
Commented by Stefan Feulner on December 12th, 2023 | 06:30 CET
Hensoldt, Defense Metals, RWE - Important milestones
Following the recent year-end rally on the world's stock markets, the chances of further price gains are good. Even in the last month of an eventful stock market year, plenty of activity remains. The course is being set with regard to the strategic goals for a successful 2024 as a whole. In addition, even in mid-December, major capital measures must be finalized before the books are closed.
Read
Commented by André Will-Laudien on December 11th, 2023 | 07:30 CET
Gold and Silver in 2024 - Breakout or Crash? Blackrock Silver, TUI and Lufthansa should show their colors now!
A new record high for the DAX at 16,782 - who would have thought it? The stock market is anything but boring at the moment. Gold started the week at a new all-time high of USD 2,147 in Asian trading, then sold off and even fell below the USD 2,000 mark again over the course of the week. Although the central banks are currently absorbing 30% of production, the price is unable to hold steady at the top. This is likely due to the lower-than-expected inflation at the beginning of the last quarter of the year. All in all, lower inflation also means lower interest rates. This is actually a bullish signal for gold and silver, but things often turn out differently than expected. On the consumption side, the tourism market should also be considered due to higher household budgets. Is this where the top yields for the coming year are hiding?
Read
Commented by Stefan Feulner on December 11th, 2023 | 07:20 CET
Infineon, First Hydrogen, Plug Power - Opportunities upon opportunities in decarbonization
Once again, 2023 was a stock market year to forget for companies in the renewable energy sector. Share price falls of around 70% for market-leading companies were the rule rather than the exception. However, decarbonization is underway, demand is rising, and the potential is huge. As a result, there are tremendous long-term opportunities for disproportionately high share price gains in selected stocks.
Read
Commented by Juliane Zielonka on December 8th, 2023 | 07:20 CET
Which stocks are leading the fight against cancer and chronic diseases? Defence Therapeutics, Merck and BioNTech
The pharmaceutical industry is facing complex developments in the fight against cancer, with Defence Therapeutics making significant progress with the successful FDA filing for its drug for the targeted treatment of tumors. The growing market opportunities in oncology until 2032 underline the potential of this breakthrough. In contrast, Merck KGaA is experiencing a severe setback with an 11% share price decline following the failure of evobrutinib for the relief of MS in late-stage clinical trials. According to analysts, this also impacts the Company's valuation. Despite promising cancer-fighting approaches, BioNTech faces uncertainties due to a reduced revenue forecast for 2023 and an 'Underweight' rating from JP Morgan. Despite these challenges, the sector remains dynamic. Find out which shares could be worthwhile in the long term here.
Read